Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Neuron|August 1, 1995
Three-dimensional location of the main immunogenic region of the acetylcholine receptorR Beroukhim, N UnwinUltramicroscopy|January 24, 1998
Distortion correction of tubular crystals: improvements in the acetylcholine receptor structureR Beroukhim, N UnwinJournal of Neurochemistry|March 1, 1995
Ultrastructure of the 5-hydroxytryptamine3 receptorF G Boess, R Beroukhim, I L MartinOncogene|December 24, 2013
TRAF2 is an NF-κB-activating oncogene in epithelial cancersR R Shen, A Y Zhou, E Kim, et al.Journal of Neuro-Oncology|December 15, 2010
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failureC Lu-Emerson, A D Norden, J Drappatz, et al.Cold Spring Harbor Symposia on Quantitative Biology|July 28, 2006
"Lineage addiction" in human cancer: lessons from integrated genomicsL A Garraway, B A Weir, X Zhao, et al.British Journal of Cancer|May 14, 2008
Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinomaI B Engelsen, M Mannelqvist, I M Stefansson, et al.Oncogene|July 20, 2007
Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomasK Takeyama, S Monti, J P Manis, et al.Oncogene|November 23, 2011
PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signalingY Shrestha, E J Schafer, J S Boehm, et al.Journal of Neuro-Oncology|October 11, 2011
Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade gliomaJ Drappatz, E Q Lee, S Hammond, et al.Pageof 2